GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Debt-to-Equity

Maat Pharma (XPAR:MAAT) Debt-to-Equity : 0.69 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma Debt-to-Equity?

Maat Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.46 Mil. Maat Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €10.62 Mil. Maat Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €20.47 Mil. Maat Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Maat Pharma's Debt-to-Equity or its related term are showing as below:

XPAR:MAAT' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.29   Med: 0.4   Max: 2.05
Current: 0.69

During the past 6 years, the highest Debt-to-Equity Ratio of Maat Pharma was 2.05. The lowest was -2.29. And the median was 0.40.

XPAR:MAAT's Debt-to-Equity is ranked worse than
80.39% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs XPAR:MAAT: 0.69

Maat Pharma Debt-to-Equity Historical Data

The historical data trend for Maat Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma Debt-to-Equity Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial -2.29 0.38 0.15 0.42 0.69

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.25 0.42 0.42 0.69

Competitive Comparison of Maat Pharma's Debt-to-Equity

For the Biotechnology subindustry, Maat Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maat Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Maat Pharma's Debt-to-Equity falls into.



Maat Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Maat Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Maat Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maat Pharma  (XPAR:MAAT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Maat Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Maat Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Maat Pharma (XPAR:MAAT) Business Description

Traded in Other Exchanges
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma (XPAR:MAAT) Headlines

No Headlines